Profile data is unavailable for this security.
About the company
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
- Revenue in USD (TTM)16.76m
- Net income in USD-72.34m
- Incorporated1969
- Employees109.00
- LocationVaxart Inc170 Harbor Way, Suite 300SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 550-3500
- Fax+1 (650) 871-8580
- Websitehttps://vaxart.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coherus Biosciences Inc | 304.34m | -450.00k | 126.73m | 235.00 | -- | -- | 26.10 | 0.4164 | -0.0892 | -0.0892 | 2.60 | -0.7636 | 0.5591 | 2.94 | 1.58 | 994,575.20 | -0.0827 | -21.43 | -0.1626 | -29.32 | 44.71 | 79.01 | -0.1479 | -36.56 | 1.09 | -3.92 | 1.50 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Cardiff Oncology Inc | 689.00k | -43.01m | 127.83m | 31.00 | -- | 2.47 | -- | 185.54 | -0.9493 | -0.9493 | 0.0152 | 1.01 | 0.0091 | -- | 1.69 | 22,225.81 | -56.80 | -31.24 | -66.22 | -33.56 | -- | -- | -6,238.17 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Fennec Pharmaceuticals Inc | 49.35m | -1.13m | 129.48m | 36.00 | -- | -- | -- | 2.62 | -0.1004 | -0.1004 | 1.75 | -0.1886 | 1.27 | 2.22 | 5.66 | -- | -2.91 | -73.43 | -3.40 | -84.32 | 93.52 | -- | -2.30 | -383.28 | 7.64 | 0.5978 | 1.21 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| TriSalus Life Sciences Inc | 26.89m | -58.65m | 129.85m | 112.00 | -- | -- | -- | 4.83 | -1.68 | -1.68 | 0.8963 | -0.6706 | 0.8812 | 1.23 | 6.75 | 240,098.20 | -181.70 | -- | -265.24 | -- | 87.10 | -- | -206.19 | -- | 2.00 | -26.43 | 17.43 | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -52.20m | 132.67m | 42.00 | -- | -- | -- | -- | -1.74 | -1.74 | 0.00 | -0.4749 | 0.00 | -- | -- | 0.00 | -145.85 | -- | -227.04 | -- | -- | -- | -- | -- | -- | -30.42 | -- | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 0.00 | -19.57m | 135.06m | 8.00 | -- | -- | -- | -- | -2.72 | -2.72 | 0.00 | -0.0711 | 0.00 | -- | -- | 0.00 | -175.81 | -66.49 | -267.87 | -85.55 | -- | -- | -- | -1,139.14 | -- | -- | -- | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Vaxart Inc | 16.76m | -72.34m | 136.30m | 109.00 | -- | 1.99 | -- | 8.13 | -0.4182 | -0.4182 | 0.0928 | 0.3009 | 0.1231 | -- | 8.18 | 153,761.50 | -53.13 | -49.60 | -80.07 | -54.86 | -- | -- | -431.61 | -1,398.00 | -- | -189.18 | 0.0665 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Black Diamond Therapeutics Inc | 0.00 | -73.10m | 137.50m | 54.00 | -- | 1.41 | -- | -- | -1.36 | -1.36 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -47.12 | -40.29 | -53.28 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -81.67m | 138.78m | 51.00 | -- | 0.639 | -- | -- | -1.37 | -1.37 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -29.52 | -- | -30.98 | -- | -- | -- | -- | -- | -- | -- | 0.1202 | -- | -- | -- | -22.20 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -7.54m | 140.80m | 1.00 | -- | 3.76 | -- | -- | -12.70 | -12.70 | 0.00 | 1.07 | 0.00 | -- | -- | 0.00 | -267.72 | -224.08 | -62,658.33 | -346.74 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.40 | -- | -- | -- |
| PepGen Inc | 0.00 | -87.23m | 140.81m | 64.00 | -- | 1.02 | -- | -- | -2.98 | -2.98 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -58.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -20.53m | 144.06m | 9.00 | -- | -- | -- | -- | -0.0241 | -0.0241 | 0.00 | -0.0699 | 0.00 | -- | -- | 0.00 | -94.20 | -259.15 | -- | -- | -- | -- | -- | -232,918.20 | -- | 1.36 | -- | -- | -- | -- | 35.70 | -- | -- | -- |
| Sagimet Biosciences Inc | 0.00 | -37.52m | 144.88m | 10.00 | -- | 0.8488 | -- | -- | -1.29 | -1.29 | 0.00 | 5.30 | 0.00 | -- | -- | 0.00 | -27.02 | -- | -27.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sio Capital Management LLCas of 30 Sep 2024 | 13.61m | 5.98% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 10.00m | 4.40% |
| Millennium Management LLCas of 30 Sep 2024 | 3.97m | 1.75% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.54m | 1.12% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.77m | 0.78% |
| SilverArc Capital Management LLCas of 30 Sep 2024 | 1.00m | 0.44% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 594.15k | 0.26% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 409.18k | 0.18% |
| Squarepoint OPS LLCas of 30 Sep 2024 | 265.01k | 0.12% |
| Susquehanna Financial Group LLLPas of 30 Sep 2024 | 259.56k | 0.11% |
